Adenin,Thymin | 210432-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: Adenin,Thymin
• 英文别名: AdeH:ThyH；Adenine-thymine；5-methyl-1H-pyrimidine-2,4-dione;7H-purin-6-amine
• CAS: 210432-81-8
• 化学式: C₅H₅N₅*C₅H₆N₂O₂
• 分子量: 261.243
• InChiKey: FFKUHGONCHRHPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.69
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  139
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-benzyliminodiacetate-copper(II) chelate 、 Adenin,Thymin 以 水 为溶剂， 生成 [Cu2(NBzIDA)2(H2O)2(μ-N7,N9-Ade(N3)H)]*3H2O
  参考文献：
  名称：

  Interligand Interactions Controlling the μ-N7,N9-Metal Bonding of Adenine (AdeH) to the N-Benzyliminodiacetato(2−) Copper(II) Chelate and Promoting the N9 versus N3 Tautomeric Proton Transfer:  Molecular and Crystal Structure of [Cu₂(NBzIDA)₂(H₂O)₂(μ-N7,N9-Ade(N3)H)]·3H₂O

  摘要：

  The reaction in water of the N-benzyliminodiacetate-copper(II) chelate ([Cu(NBzIDA)]) and the adenine:thymine base pair complex (AdeH:ThyH) with a Cu/NBzIDA/AdeH/ThyH molar ratio of 2:21:1 yields [Cu-2(NBzIDA)(2)(H2O)(2)(mu-N7,Ng-Ade(N3)H)].3H(2)O and free ThyH. The compound has been studied by thermal, spectral, and X-ray diffraction methods. In the asymmetric dinuclear complex units both Cu(II) atoms exhibit a square pyramidal coordination, where the four closest donors are supplied by NBzIDA in a mertridentate conformation and the N7 or N9 donors of AdeH, which is protonated at N3. The mu-N7,N9 bridge represents a new coordination mode for nonsubstituted AdeH, except for some adeninate(1-)-[methylmercury(II)] derivatives studied earlier. The dinuclear complex is stabilized by the Cu-N7 and Cu-N9 bonds and N6-H(exocyclic)...O(carboxyl) and N3-H(heterocyclic)...O(carboxyl) interligand interactions, respectively. The structure of the new compound differs from that of the mononuclear compound [Cu(NBzIDA)(Ade(N9)H)(H2O)].H2O, in which the unusual Cu-N3-(AdeH) bond is stabilized by a N9-H...O(carboxyl) interligand interaction and where alternating benzyl-AdeH intermolecular pi,pi-stacking interactions produce infinite stacked chains. The possibility for ThyH to be involved in the molecular recognition between [Cu(NBzIDA)] and the AdeH:ThyH base pair is proposed.

  DOI：

  10.1021/ic025881k
• 作为产物：
  描述：

  胸腺嘧啶 、 腺嘌呤 以 乙醇 为溶剂， 生成 Adenin,Thymin
  参考文献：
  名称：

  腺嘌呤和胸腺嘧啶之间的分子间2：1配合物的晶体结构。关于Hoogsteen和“准Watson-Crick”交互作用的证据

  摘要：

  通过共结晶（EtOH / 25°C）获得的标题复合物显然是唯一已知的游离碱复合物。由90 K和313 K的X射线衍射确定的晶体结构表明，一对A–T对涉及Hoogsteen相互作用，而另一对Watson-Crick相互作用涉及腺嘌呤单元。缺乏清晰的沃森-克里克碱基对引发了有关DNA双螺旋结构基础的有趣问题。

  DOI：

  10.1016/j.bmcl.2010.04.131

文献信息

• Chemical compounds
  申请人：——

  公开号：US20030120071A1

  公开（公告）日：2003-06-26

  Aryl substituted phosphoryl derivatives of the formula 1 In which Ar is phenyl, naphthyl, or pyridyl, Y is O or S, X 1 is O, NR 3 , S, CR 3 R 4 , CR 3 W 1 or CW 1 W 2 , X 2 and X 6 are a bond or X 6 is CH 2 and X 2 is O, NR 3 , S, CR 3 R 4 , CR 3 W 1 or CW 1 W 2 , R 3 and R 4 are H, alkyl or phenyl, groups, W 1 and W 2 are heteroatoms, X 3 is alkylene, X 4 is oxygen or CH 2 , X 5 is a bond or CH 2 , Z is O, NR 5 , S, alkyl or phenyl, R 5 is H, alkyl or phenyl, J is H, alkyl, phenyl, or a heterocyclic or polycyclic group, Q is O, NR 6 , S, CR 6 R 7 , CR 6 W 3 or CW 3 W 4 , R 6 and R 7 are H, alkyl or phenyl, and W 3 and W 4 are hetero atoms, T 1 and T 2 are H or CH 2 R 8 , R 8 is H, OH or F, or T 1 and T 2 together are —CH═CH— or —C(R 9 )(R 10 )C(R 11 )(R 12 )—, R 9 is H, halogeno, CN, NH 2 , CO-alkyl, or alkyl, R 10 , R 11 , and R 12 are H, N 3 , halogen, CN, NH 2 , CO-alkyl, or alkyl, and B is a purine or pyrimidine base, have antiviral activity, as for example against HIV. Particularly preferred are thymine and adenine derivatives of amino acid phenoxyphosphoroamidates. A typical embodiment is 2′,3′-dideoxy-2′,3′-didehydrothymidine 5′-(phenyl methoxy alaninyl) phosphoroamidate which can be prepared from phenyl methoxy alaninyl phosphorochloridate and 2′,3′-dideoxy-2′,3′-didehydrothymidine.

  式1中，Ar为苯基、萘基或吡啶基，Y为O或S，X1为O、NR3、S、CR3R4、CR3W1或CW1W2，X2和X6为键或X6为CH2且X2为O、NR3、S、CR3R4、CR3W1或CW1W2，R3和R4为H、烷基或苯基，W1和W2为杂原子，X3为烷基，X4为氧或 ，X5为键或 ，Z为O、NR5、S、烷基或苯基，R5为H、烷基或苯基，J为H、烷基、苯基或杂环或多环基，Q为O、NR6、S、CR6R7、CR6W3或CW3W4，R6和R7为H、烷基或苯基，W3和W4为杂原子，T1和T2为H或 R8，R8为H、OH或F，或T1和T2一起为—CH═CH—或—C(R9)(R10)C(R11)(R12)—，R9为H、卤素、CN、NH2、CO-烷基或烷基，R10、R11和R12为H、N3、卤素、CN、NH2、CO-烷基或烷基，B为嘌呤或嘧啶碱基，具有抗病毒活性，例如对HIV。特别优选的是氨基酸苯氧基磷酰胺酸的胸腺嘧啶和腺嘌呤衍生物。一个典型的实施例是2′,3′-二脱氧-2′,3′-二脱氢胸腺嘧啶5′-(苯基甲氧基丙氨酰基)磷酰胺酸，它可以由苯基甲氧基丙氨酰基磷酸氯酰和2′,3′-二脱氧-2′,3′-二脱氢胸腺嘧啶制备。
• Synthesis of chemical tags
  申请人：INTERNATIONAL BUSINESS MACHINES CORPORATION

  公开号：EP0987336A2

  公开（公告）日：2000-03-22

  A method for forming a biological chemical tag. At least one double stranded DNA molecule is provided. At least a portion of the at least one double stranded DNA molecule is denatured. At least one chemical moiety that prohibits recrystallization of the at least one denatured portion to which the at least one chemical moiety is attached is attached to at least one nucleotide in the at least one denatured portion of the at least one double stranded DNA molecule.

  一种形成生物化学标签的方法。提供至少一种双链 DNA 分子。至少一个双链 DNA 分子的至少一部分变性。在至少一个双链 DNA 分子的至少一个变性部分的至少一个核苷酸上附着至少一个化学分子，该化学分子禁止至少一个变性部分的再结晶。
• COMBINATIONS OF LIPOSOMAL IRINOTECAN, 5-FU AND LEUCOVORIN FOR THE TREATMENT OF PANCREATIC CANCER
  申请人：Ipsen Biopharm Ltd.

  公开号：EP3266456A1

  公开（公告）日：2018-01-10

  Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

  本文提供了通过单独使用或与其他治疗剂联合使用脂质体伊立替康（MM-398）治疗患者胰腺癌的方法。在一个实施方案中，脂质体伊立替康（MM-398）与 5-氟尿嘧啶和亮菌甲素联合给药。
• Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
  申请人：Ipsen Biopharm Ltd.

  公开号：US10980795B2

  公开（公告）日：2021-04-20

  Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

  本文提供了通过单独使用或与其他治疗剂联合使用脂质体伊立替康（MM-398）治疗患者胰腺癌的方法。在一个实施方案中，脂质体伊立替康（MM-398）与 5-氟尿嘧啶和亮菌甲素联合给药。
• Methods for treating pancreatic cancer using combination therapies
  申请人：Ipsen Biopharm Ltd.

  公开号：US11369597B2

  公开（公告）日：2022-06-28

  Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

  本文提供了通过单独使用或与其他治疗剂联合使用脂质体伊立替康（MM-398）治疗患者胰腺癌的方法。在一个实施方案中，脂质体伊立替康（MM-398）与 5-氟尿嘧啶和亮菌甲素联合给药。